Hybrid-nanoparticle based oxycodone vaccines: impact of carrier proteins and adjuvants on their immunogenicity 2042

Description Opioid use disorder (OUD) is responsible for the loss of hundred of thousands of Americans lives each year. It has become one of the most profound public health crises facing the United States in the past decades. Despite its devastating effect, there are few available treatments outside of the overdose reversing drugs such as naloxone. New methods for OUD treatment are urgently needed. Here, we report the development of hybrid-nanoparticle based vaccines against oxycodone, one of the most used opioid analgesics. Different carrier proteins and adjuvants were formulated into different vaccines, and the immunogenicity studies revealed that the vaccine efficacy is highly dependent on the protein and adjuvants used. The nanovaccines showed superior immunogenicity and pharmacokinetic efficacy comparing to their conjugate vaccine counterpart. This study provides evidence that hybrid nanoparticle-based vaccines are superior vaccine candidates than conjugate vaccines and will be beneficial in treating those suffering from OUD. Funding Sources National Institute on Drug Abuse (NIDA) award 5UG3DA048775 Topic Categories Vaccines and Immunotherapy (VAC)